NYC case series indicates biologics, JAK inhibitors did not worsen COVID-19 outcomes

Baseline use of biologics and JAK inhibitors among patients with immune-mediated inflammatory disease, such as rheumatoid arthritis, psoriatic arthritis, psoriasis and other related conditions, is not associated with worse COVID-19 outcomes, according to a case series presented in the New England Journal of Medicine.“Since the start of this pandemic, we have been fielding one particular call from our patients, and some colleagues — what should I do about my medications?” Rebecca Haberman, MD, of New York University Langone Health, told Healio Rheumatology. “RheumatologistsRead More

Share on facebook
Share on twitter
Share on linkedin